Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 15755514)

1.

Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia.

Collado M, Barragan E, Bolufer P, Calasanz MJ, Larrayoz MJ, Colomer D, Munarriz B, Verdeguer A, Gutierrez A, Batlle M, Sanz MA.

Leuk Res. 2005 May;29(5):595-7. Epub 2005 Jan 12. No abstract available.

PMID:
15755514
2.

Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia.

Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N, Ino T, Utsunomiya A, Maruta A, Jin-nai I, Kamada N, Kubota Y, Nakamura H, Shimazaki C, Horiike S, Kodera Y, Saito H, Ueda R, Wiemels J, Ohno R.

Clin Cancer Res. 2000 Oct;6(10):4091-5.

3.

Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.

Bangsi D, Zhou J, Sun Y, Patel NP, Darga LL, Heilbrun LK, Powell IJ, Severson RK, Everson RB.

Urol Oncol. 2006 Jan-Feb;24(1):21-7.

PMID:
16414488
4.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
5.

Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.

Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P.

Haematologica. 2007 Feb;92(2):277-8.

6.

Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.

He P, Court MH, Greenblatt DJ, Von Moltke LL.

Clin Pharmacol Ther. 2005 May;77(5):373-87.

PMID:
15900284
7.

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.

Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, Kim HS.

CMAJ. 2006 Jun 6;174(12):1715-22. Erratum in: CMAJ. 2006 Jul 4;175(1):64.

8.

Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.

Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA.

BMC Cancer. 2007 Jul 2;7:118.

9.

The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population.

Nogal A, Coelho A, Catarino R, Morais A, Lobo F, Medeiros R.

Cancer Genet Cytogenet. 2007 Sep;177(2):149-52.

PMID:
17854673
10.

Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus.

Yamada Y, Matsuo H, Watanabe S, Kato K, Yajima K, Hibino T, Yokoi K, Ichihara S, Metoki N, Yoshida H, Satoh K, Nozawa Y.

Int J Mol Med. 2007 Nov;20(5):703-7.

PMID:
17912464
11.

Atherothrombotic events and clopidogrel therapy.

Guirguis M.

CMAJ. 2007 Jan 30;176(3):349; author reply 351. No abstract available.

12.

A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations.

Reyes-Hernández OD, Lares-Asseff I, Sosa-Macias M, Vega L, Albores A, Elizondo G.

Pharmacology. 2008;81(2):97-103. Epub 2007 Oct 19.

PMID:
17952011
13.

Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP. Distribution frequencies in a Mexican population.

Reyes-Hernández OD, Arteaga-Illán G, Elizondo G.

Clin Genet. 2004 Aug;66(2):166-8. No abstract available.

PMID:
15253768
14.

Factors influencing midazolam hydroxylation activity in human liver microsomes.

He P, Court MH, Greenblatt DJ, von Moltke LL.

Drug Metab Dispos. 2006 Jul;34(7):1198-207. Epub 2006 Apr 25.

15.

CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.

Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y.

Clin Pharmacol Ther. 2007 Dec;82(6):711-25. Epub 2007 May 9.

PMID:
17495880
16.

Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects.

Ruzilawati AB, Suhaimi AW, Gan SH.

Clin Chim Acta. 2007 Aug;383(1-2):158-62. Epub 2007 May 18.

PMID:
17601520
17.
18.

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.

Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.

Clin Cancer Res. 2005 Oct 15;11(20):7398-404.

19.

Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.

DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M, Foulkes A, Gimotty P, Glick J, Weber B, Stadtmauer E, Rebbeck TR.

J Clin Oncol. 2005 Aug 20;23(24):5552-9. Erratum in: J Clin Oncol. 2007 Dec 10;25(35):5675-7. Retraction in: J Clin Oncol. 2006 Jul 10;24(20):3315.

20.

CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans.

Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, Conde B, Arenaz I, Martinez-Jarreta B.

Ther Drug Monit. 2007 Aug;29(4):412-6.

PMID:
17667794
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk